MedPath

Amphetamine

Generic Name
Amphetamine
Brand Names
Adderall, Adzenys, Dyanavel, Evekeo, Mydayis
Drug Type
Small Molecule
Chemical Formula
C9H13N
CAS Number
300-62-9
Unique Ingredient Identifier
CK833KGX7E
Background

Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 and first synthesized by 1927. After being proven to reduce drug-induced anesthesia and produce arousal and insomnia, amphetamine racemic mix was registered by Smith, Kline and French in 1935. Amphetamine structure presents one chiral center and it exists in the form of dextro- and levo-isomers. The first product of Smith, Kline and French was approved by the FDA on 1976.

During World War II, amphetamine was used to promote wakefulness in the soldiers. This use derived into a large overproduction of amphetamine and all the surplus after the war finalized ended up in the black market, producing the initiation of the illicit abuse.

Indication

Amphetamine is indicated for the treatment of attention-deficit/hyperactivity disorders (ADHD) as well as for the treatment of central nervous system disorders such as narcolepsy.

ADHD is a complex disorder associated with the substantial heterogeneity in etiology, clinical presentation, and treatment outcome. ADHD comes from a complex interplay between interdependent genetic and non-genetic factors which cause complex mental disorders in children and teenagers.

On the other hand, narcolepsy is a chronic sleep disorder typically resenting during adolescence and characterized by excessive daytime sleepiness.

Amphetamine is also being used nowadays off-label for the treatment of obesity, depression and chronic pain.

Associated Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Chronic Pain, Depression, Narcolepsy, Obesity
Associated Therapies
-
papers.ssrn.com
·

Compounding Inequities Through Drug Shortages and IP Litigation

The U.S. faces its worst drug shortage in over a decade, with over 300 drugs affected. Compounding pharmacies fill critical gaps by creating unavailable medications, but face IP litigation from drug manufacturers. This article explores the conflict between FDA regulations and IP law, proposing solutions like a patent use exception and name suffixes to ensure patient access to essential drugs.
foxnews.com
·

Amid ADHD drug shortage, FDA approves generic version of medication: 'Opportune time'

The FDA approved generic versions of Vyvanse to address ADHD medication shortages, benefiting those 6 and older. Generics aim to match brand-name efficacy and cost less, potentially easing shortages, especially of Adderall. Fourteen companies can now produce generic Vyvanse, also used for binge-eating disorder in adults.
cnn.com
·

FDA, DEA call on drugmakers to boost manufacturing amid ongoing shortage of prescription stimulants

US faces a persistent Adderall shortage, with FDA and DEA urging drugmakers to increase production and healthcare providers to monitor prescriptions. Factors include a surge in demand and manufacturing delays. DEA is reviewing production quotas and calls for better ADHD diagnosis and treatment guidelines.
wweek.com
·

State Inaction Left Oregon Teens Vulnerable to Fentanyl’s Lethal Spread

Oregon faces a severe fentanyl crisis among teens, with drug-related deaths increasing faster than any other state. Despite available tools, state officials failed to act, leading to a lack of prevention and treatment services. Efforts like Senate Bill 238 aim to educate on fentanyl dangers, but youth addiction treatment resources are critically insufficient.

Centrally Acting Drugs for Obesity: Past, Present, and Future

The article reviews centrally acting anti-obesity drugs, detailing their mechanisms, efficacy, side effects, and market withdrawals due to adverse effects. It covers historical drugs like amphetamine, aminorex, fenfluramine, phenylpropanolamine, and newer drugs such as lorcaserin, liraglutide, and combinations like bupropion/naltrexone and phentermine/topiramate. The focus is on their impact on weight loss, associated risks, and the evolution of obesity treatment strategies.
pmc.ncbi.nlm.nih.gov
·

Current and emerging rehabilitation for concussion

Concussion rehabilitation lacks robust evidence, with physical and cognitive rest as the cornerstone, despite limited research. Emerging strategies like vestibular, oculomotor, and pharmacological interventions show promise but require further study. Recovery is highly individualized, suggesting a need for tailored rehabilitation approaches.
govinfo.gov
·

Rogue Online Pharmacies: The Growing Threat

The hearing addressed the growing issue of rogue online pharmacies facilitating illegal drug trafficking, particularly of addictive prescription drugs. Senators and witnesses highlighted the ease with which controlled substances can be purchased online without proper prescriptions, posing significant risks to public health, especially among youth. The discussion emphasized the need for stricter regulations, including in-person consultations for prescriptions and the certification of online pharmacies. Witnesses shared personal stories and data illustrating the severity of the problem, advocating for legislative action to combat the illegal sale of prescription drugs over the internet.
© Copyright 2025. All Rights Reserved by MedPath